Categories
Zim Laboratories Limited — Updates, 19-05-2026: General Updates
19-05-2026 · 07:15 pm
Zim Laboratories saw FY26 operating income at ₹374.4 Cr, EBITDA at ₹41.4 Cr, impacted by geopolitical issues. The company secured 34 Marketing Authorizations, expanded leadership, and saw successful CAPA remediation. A ₹35 Cr preferential share issue was approved, strengthening its innovative product pipeline.
No comments yet. Be the first to comment!